Healthcare Business - Page 2

Wow

Major Biotechs Scare Off Loads of Short Sellers

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

What Is Driving CVS Revenue Growth?

When CVS Health Corp. (NYSE: CVS) reported its fourth-quarter financial results before the markets opened on Thursday, the company posted $1.71 in earnings per share (EPS) and $46.0 billion in ...
Read Full Story »
Jon's friends

Is This the Big Turnaround Acorda Needs?

Shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) saw a handy gain in early trading on Thursday after the company reported results from its late-stage Parkinson’s trial. Basically, the company announced Phase ...
Read Full Story »
thumbs up and down

What Analysts Are Saying About Gilead Sciences After Earnings

After Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday, the stock hit a new multiyear low, not seen since 2014. Across the board analysts saw ...
Read Full Story »
Prescription Drugs, Pills

Wednesday’s Biggest Biopharma Movers

Not that many biotech and pharma companies were on the move Wednesday, but a few of the smaller caps made splash, while one giant company posted a massive loss. Although ...
Read Full Story »
burning cash

Why Gilead Earnings Were Not Up to Snuff

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter earnings after markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the ...
Read Full Story »
Pills and tablets

Is Teva’s CEO Departure Long Overdue?

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) saw its shares tumble on Tuesday after the company announced a changing of the guard for its CEO position. The company reported that Dr. ...
Read Full Story »
Medical vaccine in shoulder, vaccination

What to Expect From Gilead Earnings

Gilead Sciences Inc. (NASDAQ: GILD) is set to report its fourth-quarter financial results after the markets close on Tuesday. The consensus estimates call for $2.61 in earnings per share (EPS) ...
Read Full Story »
medical cannabis

Why Cannabinoid Developer GW Pharma Looks Better Than Ever to Investors

The world's largest company involved with producing therapeutics derived from cannabis posted a fiscal first-quarter loss of $19.25 million Tuesday morning, and the stock traded higher by about 3.5% early ...
Read Full Story »
Prescription drugs

Why Neos Therapeutics Shares Are Hitting a New Low

Neos Therapeutics Inc. (NASDAQ: NEOS) saw its shares sink to a new 52-week low after the company announced that it had priced its secondary offering of common stock. Neos priced ...
Read Full Story »
thumbs up

Why Amgen Earnings Are So Incredible

Amgen Inc. (NASDAQ: AMGN) reported fourth-quarter financial results after markets closed on Thursday. This biotech giant posted $2.89 in earnings per share (EPS) and $5.97 billion in revenue, versus consensus ...
Read Full Story »
blue eye

Why Benitec More Than Doubled

Benitec Biopharma Ltd. (NASDAQ: BNTC) saw its shares more than double on Tuesday after the company gave a business update on its ddRNAi technology for the development of therapeutics for ...
Read Full Story »
Female patient on gurney

Why Amag Pharmaceuticals Is Sinking Despite Positive Top-Line Results

AMAG Pharmaceuticals Inc. (NASDAQ: AMAG) saw its shares take a sharp turn down after the company reported top-line results from its most recent pharmacokinetic (PK) study. The results were ultimately ...
Read Full Story »
Medical vaccine in shoulder, vaccination

Why Merck’s Q4 Earnings Aren’t Enough for Investors

Merck & Co. (NYSE: MRK) reported its fourth-quarter financial results before the markets opened on Thursday. The company posted $0.89 in earnings per share (EPS) and $10.12 billion in revenue, ...
Read Full Story »